JEFFERSON CITY, Mo. — Agrochemical maker Bayer will pay up to $7.25 billion over two decades to resolve thousands of claims from U.S. cancer patients asserting the company should have warned people that its popular weedkiller Roundup could cause lymphoma, according to a settlement approved Friday by a Missouri judge.
The nationwide settlement applies both to Roundup users who already are ill and those who become diagnosed with non-Hodgkin lymphoma in future years. Participants could get an average of between $10,000 and $165,000, depending on how they used the product, how old they were when diagnosed and the severity of their illness.
For Germany-based Bayer, which denies that Roundup causes cancer, the settlement provides some financial certainty against mounting litigation costs that have led it to contemplate pulling the product from U.S. agricultural markets.
Litigants also faced uncertainty. While the settlement was pending, the U.S. Supreme Court undercut one of the central arguments in the Roundup lawsuits. The high court ruled in June that Bayer cannot be sued in state courts on claims it failed to warn about cancer, because federal regulations don't require a cancer warning label and states are forbidden from imposing additional labeling requirements.
Though some attorneys for cancer patients contend the settlement payouts are too small, others argue the deal is better than getting nothing — which became a heightened likelihood after the Supreme Court ruling.
In a written judgment granting approval, St. Louis Circuit Judge Timothy Boyer said the average individual payouts are “fair and adequate” and the total dollar amount is “among the largest in the history of mass tort personal-injury class action settlements.”
Bayer CEO Bill Anderson said in a statement that the court-approved settlement is “a decisive milestone in the company’s strategy to mitigate the risks of both pending and future Roundup litigation."
The decision could be appealed.
Roundup has been used on weeds for over 50 years
Missouri-based Monsanto debuted Roundup weedkiller in 1974 with the chemical glyphosate as its active ingredient. The product quickly became one of the most widely used herbicides in agriculture. Roundup is designed to be used with genetically modified seeds that can resist the weedkiller’s deadly effect, thus allowing farmers to produce more while conserving the soil by tilling it less.
The product also is commonly applied on lawns and gardens.
Bayer added Roundup to its portfolio when it acquired Monsanto in 2018. With it came a growing number of lawsuits alleging glyphosate causes non-Hodgkin lymphoma. But that remains in dispute. The World Health Organization's International Agency for Research on Cancer classified the chemical as "probably carcinogenic" in 2015. The U.S. Environmental Protection Agency has determined that it's not likely to cause cancer in humans when used as directed.
About 200,000 Roundup-related claims have been made against Bayer, many coming from people who used it on residential lawns and gardens. As a result, Bayer has removed glyphosate from its new versions of Roundup sold for residential markets.
The lawsuits have produced mixed results. Only a couple dozen cases have gone to jurors, some siding with Bayer and others with plaintiffs. In one case, a Georgia jury awarded plaintiffs $2.1 billion.
In the first Roundup verdict since the Supreme Court's precedent-setting ruling, a Missouri jury in October sided with Bayer in a case alleging design defects, negligence and fraud. The verdict "should send a strong signal" that plaintiffs "will face significant challenges" pursuing Roundup-related cancer claims in the future, said Bill Dodero, Bayer's U.S. general counsel and global litigation leader.